RB0.F REGENXBIO Inc

Healthcare Biotechnology Frankfurt Exchange
7.14 EUR
Close of Nov 13, 2026
4.73 13.60
Market cap
EUR 472M
P/E
-
P/B
3.44x
ROE
-97.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RB0.F undervalued?

Graham number

The Graham number of REGENXBIO Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

REGENXBIO Inc fundamental analysis

No fundamental analysis for REGENXBIO Inc yet.

REGENXBIO Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-…

Full company profile